Showing results (161-170 of 863) with videos related to
Sort By:
Pageof 87
Clinical Pharmacokinetics|December 17, 2008
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in developmentBengt I Eriksson, Daniel J Quinlan, Jeffrey I WeitzEuropean Heart Journal|March 29, 2023
Reversal agents for current and forthcoming direct oral anticoagulantsNick van Es, Raffaele De Caterina, Jeffrey I WeitzHematology. American Society of Hematology. Education Program|November 10, 2001
Advances in Therapy and the Management of Antithrombotic Drugs for Venous ThromboembolismJack E. Ansell, Jeffrey I. Weitz, Anthony J. ComerotaJournal of Thrombosis and Haemostasis : JTH|June 8, 2025
DOAC-Stop reverses the anticoagulant effect of asundexian and milvexianElla K Fitzpatrick, James C Fredenburgh, Jeffrey I WeitzF1000Research|July 18, 2017
Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulantsJeffrey I Weitz, Iqbal H Jaffer, James C FredenburghBlood|June 14, 2014
Evolving use of new oral anticoagulants for treatment of venous thromboembolismCalvin H Yeh, Peter L Gross, Jeffrey I WeitzCirculation Research|February 1, 2019
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular DiseaseMichiel Coppens, Jeffrey I Weitz, John W A EikelboomJournal of the American College of Cardiology|November 4, 2017
A Test in Context: D-DimerJeffrey I Weitz, James C Fredenburgh, John W EikelboomCirculation Research|October 2, 2012
Oral direct factor Xa inhibitorsCalvin H Yeh, James C Fredenburgh, Jeffrey I WeitzBlood|October 27, 2016
Emerging anticoagulant strategiesJames C Fredenburgh, Peter L Gross, Jeffrey I WeitzPageof 87